FDA Approves New Class of Oral Medicines for Children with Type 2 Diabetes
Portfolio Pulse from Vandana Singh
The FDA has approved Jardiance and Synjardy, new oral medicines for children with type 2 diabetes, providing a new class of treatments. The approvals were granted to Boehringer Ingelheim, which has an alliance with Eli Lilly And Co (NYSE:LLY) in diabetes treatment.
June 21, 2023 | 12:32 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Eli Lilly's alliance with Boehringer Ingelheim benefits from FDA approval of Jardiance and Synjardy for pediatric type 2 diabetes treatment.
The FDA approval of Jardiance and Synjardy expands the treatment options for pediatric type 2 diabetes, which could lead to increased sales and revenue for Eli Lilly and Boehringer Ingelheim. As a result, this news is likely to have a positive short-term impact on Eli Lilly's stock price.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 80